CN1222519C - 间质金属蛋白酶的反异羟肟酸酯抑制剂 - Google Patents

间质金属蛋白酶的反异羟肟酸酯抑制剂 Download PDF

Info

Publication number
CN1222519C
CN1222519C CNB008032378A CN00803237A CN1222519C CN 1222519 C CN1222519 C CN 1222519C CN B008032378 A CNB008032378 A CN B008032378A CN 00803237 A CN00803237 A CN 00803237A CN 1222519 C CN1222519 C CN 1222519C
Authority
CN
China
Prior art keywords
phenyl
ethyl
hydroxyl
alkylsulfonyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008032378A
Other languages
English (en)
Chinese (zh)
Other versions
CN1339032A (zh
Inventor
M·L·库尔丁
戴瑜嘉
S·K·戴维森
H·R·海曼
J·H·霍尔梅斯
M·R·米歇利德斯
D·H·斯坦曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1339032A publication Critical patent/CN1339032A/zh
Application granted granted Critical
Publication of CN1222519C publication Critical patent/CN1222519C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB008032378A 1999-01-27 2000-01-27 间质金属蛋白酶的反异羟肟酸酯抑制剂 Expired - Fee Related CN1222519C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27
US09/239087 1999-01-27
US09/239,087 1999-01-27

Publications (2)

Publication Number Publication Date
CN1339032A CN1339032A (zh) 2002-03-06
CN1222519C true CN1222519C (zh) 2005-10-12

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008032378A Expired - Fee Related CN1222519C (zh) 1999-01-27 2000-01-27 间质金属蛋白酶的反异羟肟酸酯抑制剂

Country Status (28)

Country Link
US (1) US20020007060A1 (https=)
EP (1) EP1147101B1 (https=)
JP (1) JP4718686B2 (https=)
KR (1) KR100748010B1 (https=)
CN (1) CN1222519C (https=)
AR (1) AR029329A1 (https=)
AT (1) ATE228122T1 (https=)
AU (1) AU764383B2 (https=)
BG (1) BG105782A (https=)
BR (1) BR0007278A (https=)
CA (1) CA2358951C (https=)
CO (1) CO5150194A1 (https=)
CZ (1) CZ20012591A3 (https=)
DE (1) DE60000819T2 (https=)
DK (1) DK1147101T3 (https=)
ES (1) ES2187443T3 (https=)
HK (1) HK1043115A1 (https=)
HU (1) HUP0105477A2 (https=)
IL (1) IL143713A0 (https=)
NO (1) NO20013669L (https=)
NZ (1) NZ512372A (https=)
PL (1) PL349771A1 (https=)
PT (1) PT1147101E (https=)
SK (1) SK10582001A3 (https=)
TR (1) TR200102159T2 (https=)
TW (1) TWI225486B (https=)
WO (1) WO2000044739A1 (https=)
ZA (1) ZA200104979B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2003063762A2 (en) * 2001-01-12 2003-08-07 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
DE60230781D1 (en) 2001-09-07 2009-02-26 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren

Also Published As

Publication number Publication date
CZ20012591A3 (cs) 2001-12-12
JP4718686B2 (ja) 2011-07-06
PT1147101E (pt) 2003-04-30
ZA200104979B (en) 2002-09-18
ES2187443T3 (es) 2003-06-16
TWI225486B (en) 2004-12-21
JP2002535398A (ja) 2002-10-22
IL143713A0 (en) 2002-04-21
EP1147101B1 (en) 2002-11-20
NO20013669D0 (no) 2001-07-26
US20020007060A1 (en) 2002-01-17
BG105782A (en) 2002-04-30
CO5150194A1 (es) 2002-04-29
AU764383B2 (en) 2003-08-14
DE60000819D1 (de) 2003-01-02
HUP0105477A2 (hu) 2002-05-29
TR200102159T2 (tr) 2001-12-21
WO2000044739A1 (en) 2000-08-03
HK1043115A1 (zh) 2002-09-06
CN1339032A (zh) 2002-03-06
BR0007278A (pt) 2001-11-27
DE60000819T2 (de) 2003-09-04
ATE228122T1 (de) 2002-12-15
SK10582001A3 (sk) 2001-12-03
DK1147101T3 (da) 2003-03-10
KR100748010B1 (ko) 2007-08-09
CA2358951C (en) 2009-10-20
NZ512372A (en) 2003-01-31
AR029329A1 (es) 2003-06-25
AU2739100A (en) 2000-08-18
KR20010101709A (ko) 2001-11-14
EP1147101A1 (en) 2001-10-24
NO20013669L (no) 2001-09-27
PL349771A1 (en) 2002-09-09
CA2358951A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
CN1273467C (zh) β－内酰胺化合物、这些化合物的制备方法以及含有这些化合物的降血清胆固醇药
CN1207289C (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1051308C (zh) 噁唑烷－2－酮衍生物和含有这些物质的药物
CN1229405A (zh) 新颖的乙酰胺衍生物和蛋白酶抑制剂
CN1178906C (zh) 基质金属蛋白酶的逆异羟肟酸盐抑制剂
HK1049118A1 (zh) 金属蛋白酶抑制剂
CN1028529C (zh) 内亚苯基氧杂双环庚基取代的前列腺素类似物的制法
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN1197458A (zh) 具有磷酯酶a2抑制活性的吡咯烷衍生物
CN1037144A (zh) 用作为消炎剂和抗退化剂的新的取代的氮氧杂丁酮
CN1046937C (zh) 木酚素系化合物的制备方法
CN1968945A (zh) 用于抑制β分泌酶的氨基－5,5－二苯基咪唑酮衍生物
CN1281433A (zh) 作为基质金属蛋白酶(mmp)抑制剂的异羟肟酸衍生物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1620424A (zh) 治疗炎性疾病的化合物
CN1152877C (zh) 哌嗪衍生物
CN1571786A (zh) 烷基醚衍生物或其盐
CN1320123A (zh) 二取代马来酰亚胺化合物及其医药用途
CN1819996A (zh) 作为细胞色素p450抑制剂的亚萘基衍生物
CN1829519A (zh) 二苯基取代的环烷烃类,含有它们的组合物和应用的方法
CN1195343A (zh) 哌啶衍生物及其用途
CN1291979C (zh) 咪唑化合物及其作为腺苷脱氨酶抑制剂的用途
CN1222519C (zh) 间质金属蛋白酶的反异羟肟酸酯抑制剂
CN1284942A (zh) 基质金属蛋白酶抑制剂
CN1675180A (zh) 吲哚、吲唑和氮茚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee